Evidence map›Paper›PMID 39576031›Full record

ArticleEuropean journal of rheumatology2024

Clinical Phenotypes of Giant Cell Arteritis: Insights into Complications and Survival Outcomes.

Paula Estrada, Javier Narváez, Patricia Moya, Daniel Roig-Vilaseca, Oscar Camacho, Vanessa Navarro, Sergi Heredia, Dacia Cerdà, Delia Reina, Hèctor Corominas

Abstract read
In one paragraph

Article in European journal of rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paula EstradaDepartment of Rheumatology, Complex Universitari Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
Javier NarváezDepartment of Rheumatology, Hospital Universitari Bellvitge, L'Hospitalet de LLobregat, Barcelona, Spain.
Patricia MoyaDepartment of Rheumatology, Hospital Universitari Bellvitge, Universitat de Barcelona (UB), L'Hospitalet de LLobregat, Barcelona, Spain.
Daniel Roig-VilasecaDepartment of Rheumatology, Complex Universitari Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
Oscar CamachoDepartment of Rheumatology, Complex Universitari Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
Vanessa NavarroDepartment of Rheumatology, Complex Universitari Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
Sergi HerediaDepartment of Rheumatology, Complex Universitari Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
Dacia CerdàDepartment of Rheumatology, Complex Universitari Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
Delia ReinaDepartment of Rheumatology, Complex Universitari Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
Hèctor CorominasDepartment of Rheumatology, Hospital Universitari Bellvitge, Universitat de Barcelona (UB), L'Hospitalet de LLobregat, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Giant cell arteritis (GCA) is a heterogeneous disease with diverse clinical presentations and varying degrees of severity. This study aimed to assess the incidence of 3 clinical subsets in GCA and analyze associated severe complications and survival rates. By identifying distinct clinical patterns, the goal is to customize treatment approaches and minimize severe complications during follow-up. Methods: This retrospective study classified clinical manifestations of GCA into 3 major phenotypes based on the reason for consultation: i) cranial, ii) extracranial, and iii) occult GCA. These groups were analyzed and compared for acute complications, including severe ischemic complications, "true" occlusive disease, and late complications such as aortic aneurysm. Survival data were also collected during follow-up. Results: Visual disturbances were more common in the cranial GCA group compared to other subsets (P < .001). Blindness and stroke showed a clinically relevant trend, although statistical differences were not significant between the cranial GCA groups. Limb claudication was significantly more prevalent in the extracranial subset compared to the cranial or occult GCA subsets (12% vs. 2.6% vs. 0% respectively). Severe ischemic complications and true occlusive disease were more frequent in the cranial GCA groups (60%, P=.005 and 40%, P=1.64 respectively). Regarding mortality, there were no statistically significant differences in survival among the different clinical subsets. However, the occult GCA subset showed a trend towards a higher prevalence of deaths, both overall and specifically due to GCA. Conclusion: Clinical subsets in GCA present distinct complications and survival outcomes, with the cranial subset showing a higher incidence of severe ischemic events and the occult subset associated with delayed diagnosis and increased mortality. Recognizing these subsets is crucial for tailored treatment approaches and improving patient prognosis. Further prospective studies are needed to refine diagnostic and therapeutic strategies.

Indexed as

Clinical subsetsgiant cell arteritismortalitysevere ischemic complicationstrue occlusive disease

Identifiers

PMID39576031
PMCPMC11448687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.